1 Min Read How Do T Cells Kill Cancer Cells?
July 14, 2026How Do T Cells Kill Cancer Cells?
July 14, 2026
Care Framework & Diagram
When the immune system decides to kill a cancer cell, how exactly does a T cell do it?
By the Editors Care Framework & Diagram
On patrol
TCR Scans for a Match
The T cell circulates until its receptor detects a cancer marker riding on MHC-I.
Minutes
The Synapse Locks In
Adhesion molecules weld the two cells together; the kill zone lines up precisely with the target's surface.
Weapon delivery
Perforin Opens the Door
Perforin punches a channel into the membrane; granzyme B slips through and trips the cell's own self-destruct switch.
Result
Clean Apoptosis, Not Mess
DNA is systematically fragmented, the cell compacts into tidy pieces, and macrophages clear it away — no inflammation, no collateral damage.
Repeat
On to the Next Target
The T cell detaches and moves on — one cell can kill again and again.
Frequently Asked Questions
Why do some cancers achieve complete remission then relapse?
Relapse mechanisms typically include: tumor clone escape (the few cancer cells with evasion mutations survive and selectively expand under immune pressure); immune memory exhaustion (insufficient memory T cell numbers or function to sustain immune surveillance); and tumor microenvironment reconstruction (residual tumor cells rebuild immunosuppressive microenvironment). This is why maintenance therapy and close monitoring after complete remission are so critical.
How do tumor vaccines use the T cell cancer-killing mechanism?
Individualized tumor vaccines (neoantigen vaccines) target the specific neoantigens of a particular patient's tumor — through mRNA or peptide formulations, guiding dendritic cells in the body to present these neoantigens, activating the patient's own CD8+ T cells to produce memory T cells specific to these neoantigens, persistently clearing tumor cells carrying those neoantigens. Individualized tumor neoantigen vaccines (like BNT111, mRNA-4157) are showing promising early results in melanoma and other high-mutational burden tumors.
Why are solid tumors harder to treat with CAR-T than blood cancers?
Mainly because of several challenges: solid tumor microenvironments are highly immunosuppressive (Treg cells, tumor-associated macrophages, TGF-β) — CAR-T cells entering are quickly suppressed or exhausted; solid tumors' physical barriers (dense stroma) make CAR-T penetration difficult; solid tumors lack an ideal target antigen like CD19 that is 'only on tumor cells, not on important normal tissues'; and solid tumors' high heterogeneity makes single-target CAR-T therapy easily defeated by tumor clone escape.
Can PD-1 inhibitors and CAR-T be used together?
Yes, and this is an active research direction. The combination logic is clear: CAR-T cells in tumor microenvironments similarly exhaust through PD-L1/PD-1 signaling. PD-1 inhibitors can help maintain CAR-T cell activity in tumor microenvironments, preventing premature exhaustion. Early clinical data shows this combination strategy has some advantage, but may also increase risks of side effects like cytokine release syndrome — requiring careful dosing and timing design.